EPISODE · Sep 3, 2026 · 1H 29M
This Peptide Burns Fat and Builds Muscle — But the Man Who Discovered It Won't Take It - Yet
from The Living Room Podcast · host Chris Wharton
What's actually in the syringe when you buy a peptide off the black market?Now that the FDA regulation around 6 of these black market peptides is changing, should you be taking them?Should you be concerned about the link between GLP-1 use and lean tissue loss?Dr. Pinchas Cohen, PhD, is the scientist who co-discovered humanin and MOTS-c — two of the mitochondrial-derived peptides now driving the biggest wave of interest in longevity science — and he currently serves as Dean of the USC Leonard Davis School of Gerontology.Peptides have become a catch-all buzzword for a category that actually spans thousands of distinct molecules, most of them still unstudied. Dr. Cohen's lab discovered several of the ones people are now injecting themselves with, and he's spent the last year watching an unregulated market grow around his own research — to the point where he tested his friends' black-market MOTS-c and found some vials contained none of the peptide at all.Up to 30% of the weight lost on GLP-1 drugs is muscle. A genetic variant found in Ashkenazi Jews makes carriers roughly 20 times more likely to live to 100 and appears to blunt the effects of the biggest known Alzheimer's risk gene. In mice, MOTS-c extended lifespan by 10% and prevented the muscle and bone loss associated with GLP-1 use. And in July, 2026, Dr. Cohen testified in front of the FDA panel now reviewing MOTS-c's regulatory path.In this episode you'll learn:Why "peptides" make out three fundamentally different categories of molecules, not one trendHow MOTS-c and humanin were discovered inside DNA once dismissed as "junk"Why up to 30% of GLP-1 weight loss is muscle, and what that means over a decade of useWhat happened when Dr. Cohen tested the actual purity of black-market MOTS-cThe genetic variant linked to a 20x greater chance of living to 100Why he — the scientist who discovered MOTS-c — won't take it himself yetWhat the FDA's 503A compounding pathway means for legal access to peptidesWhere Alzheimer's and Parkinson's peptide research stands todayWant to learn more? Each month, we send a newsletter curated by our scientific council on what's actually advancing the science of human longevity — and what isn't. Subscribe at https://www.thewndrlab.com/mailing-listCheck out The WNDR LabConnect with Dr. Pinchas CohenConnect with our host Chris Wharton on Instagram: instagram.com/chriswharton1 Follow The LIVING Room Podcast on Socials:Instagram: https://www.instagram.com/the.living.room.pod/LinkedIn: linkedin.com/company/wndrlab/The WNDR Lab: https://www.thewndrlab.com/Show NotesStudies & Institutions referencedHealth and Retirement Study Kumagai's Japanese cohort GWAS (Genome-Wide Association Study)USC Leonard Davis School of Gerontology503AFDA PCAC panel Peptides & molecules HumaninMOTS-cSHLP SHMOOSE IGF-1, IGFBP-3ApoE4 / APOE (Alzheimer's risk gene)
Embed this episode
What this episode covers
What's actually in the syringe when you buy a peptide off the black market? Now that the FDA regulation around 6 of these black market peptides is changing, should you be taking them? Should you be concerned about the link between GLP-1 use and lean tissue loss? Dr. Pinchas Cohen, PhD, is the scientist who co-discovered humanin and MOTS-c — two of the mitochondrial-derived peptides now driving the biggest wave of interest in longevity science — and he currently serves as Dean of the USC Leona...
Ready to play
This Peptide Burns Fat and Builds Muscle — But the Man Who Discovered It Won't Take It - Yet
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.